Plain-English translation of NCT07264569 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing BioTTT001, a new treatment made from a modified virus that is injected directly into the fluid around your brain and spinal cord. The study is designed for people with non-small cell lung cancer that has come back or gotten worse after standard treatment, and has spread to the membranes surrounding the brain. Researchers want to learn if this medication is safe, how well it works, and how it travels in your body.
When lung cancer spreads to the brain and spinal fluid, it becomes very hard to treat with standard medications because most drugs cannot reach these areas well. This trial exists to see if this new virus-based treatment, delivered directly to where the cancer is, can help people with this serious condition.
You likely qualify if…
You likely don't qualify if…
You would have a small device (Ommaya reservoir) placed under your scalp to receive the medication directly into the fluid around your brain and spinal cord. During the first week, you would receive three injections, then one injection every three weeks after that. The trial has two phases: in the first phase, you may receive up to 6 doses while doctors test different dose levels; in the second phase, you would continue treatment until your cancer progresses, you experience unacceptable side effects, or you and your doctor decide to stop.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China